Santen Expands License Agreement with Aerie for Rhopressa and Rocklatan | Market Scope
ESCRS - Aerie in Europe
AERIE PHARMACEUTICALS, INC. NPS 2022
Is Aerie Pharmaceuticals Ireland Ltd. late reporting EU clinical trials?
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions | Business Wire
EX-99.1
Aerie to build manufacturing facility in Ireland
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
Glaucoma Physician - February 12, 2021
Aerie launches Ph3 trial for Roclatan eye drug in Europe - Drug Delivery Business
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
AERIE PHARMACEUTICALS, INC. 10K 2021
Form 8-K AERIE PHARMACEUTICALS For: Jan 12
Alcon Completes Acquisition of Aerie Pharmaceuticals - Eyewire+
Articles about Aerie Pharmaceuticals, Inc. | page 5
Aerie Pharmaceuticals, Inc. (Aerie Pharmace) Stock Price & News | AERI
EX-99.1
Aerie Pharmaceuticals gets $88M upfront in licensing agreement with Santen - Triangle Business Journal
Articles about Aerie Pharmaceuticals, Inc. | page 4
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Alcon to buy Aerie Pharmaceuticals for $770M - News - MM+M
